alexa
Reach Us +1-217-403-9671
Role Of Regulatory Affairs For Health Care Products | 7390
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Role of regulatory affairs for health care products

2nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

T.S. Jaishankar

ScientificTracks Abstracts: Pharmaceut Reg Affairs

DOI: 10.4172/2167-7689.S1.002

Abstract
The Government of India (GOI) regulatory regime designed to ensure the quality, safety and performance of health care products. Legislation is under way in the Parliament and officials in the Ministry of Health and Family Welfare (MoHFW) and Drugs Controller General of India (DCG(I)), to ensure maintain quality of health care products by licensing, certification and accreditation. National regulatory decisions are in line with international guidelines and ensure that the policies are adopted. GOI wanted to ensure the continued flow of safe and effective health care products in India. India?s medical device and pharmaceutical regulations and the centralized regulatory authority includes DST and CDA that distinguishes between pharmaceuticals and medical devices and has adequate powers to ensure standards, efficacy, safety and availability of health care products manufactured or marketed in the country. The MoHFW, DCG(I), BSI and Nuclear Medicine Board of the BARC regulate different aspects of the healthcare sector. Companies must register all products with the CDSCO before the company?s products can be introduced into the Indian market. Representatives from industry and GOI officials discussed a ?road map? included a current status review as well as guiding principles and a regulatory process implementation phases to make it an all inclusive process. At present the drug and pharmacy Acts and Rules are govern the manufacture, sale, import, export and clinical research of drugs and cosmetics in India. And essentially empowers the Indian Government to formulate rules specifying the operational conditionality?s of health care products in India by an efficient regulatory system.
Biography
Mr. TS Jaishankar has completed his B.Sc Honours Chemistry degree from Mumbai University. He is the managing director of Quest Lifesciences (P) ltd, Member advisory board in the journal of clinical studies UK, Member advisory board in Pharmabiz publication, Chairman of Chemech laboratories and CIPI chairman of Confederation of Indian Pharmaceutical industry. He has published several articles in the clinical trials in leading pharmaceutical magazines and he has given several talks on clinical research in reputed research academic organizations especially on BABE studies and Good Clinical Practice.
Top